FDA
-
-
-
-
-
-
-
Biofrontera reports positive Phase 2b acne trial results for Ameluz
-
-
-
-
-
-
-
Biofrontera Announces Positive Results in Phase 3 Study of Ameluz® PDT for Actinic Keratoses on the Extremities, Neck, and Trunk, Meeting Primary Endpoint
-
-
-
-
-
-
-
Biofrontera files FDA application for skin cancer treatment
-
-
-
-
-
-
-
Biofrontera Inc. Announces Last Patient Out in Phase 3 Study of Ameluz® (aminolevulinic acid HCI) Topical Gel, 10% Photodynamic Therapy (PDT) for the Treatment of Actinic Keratoses (AK) on the Extrem
-
-
-
-
-
-
-
Biofrontera Inc. Announces Patent for Propylene Glycol-Free Formula of Ameluz® (aminolevulinic acid HCI) Topical Gel, 10% Now Listed in FDA Orange Book
-
-
-
-
-
-
-
Biofrontera Inc. (BFRI) Announces 100 RhodoLED XL Machines Now Placed in US Market
-
-
-
-
-
-
-
Roth/MKM Reiterates Buy Rating on Biofrontera (BFRI)
-
331,678 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

